Substance / Medication

Esmolol hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

12 trials linked to this intervention

12
Total Trials
1
Recruiting
4
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Defibrillation strategies for patients with refractory ventricular fibrillation: A systematic review and meta-analysis.
Yu Jinzhou, Yu Yanwu, Liang Huoyan et al. · Am J Emerg Med · 2024
PMID: 39127020Meta-Analysis
Efficacy of stellate ganglion block in treatment of electrical storm: a systematic review and meta-analysis.
Motazedian Pouya, Quinn Nicholas, Wells George A et al. · Sci Rep · 2024
PMID: 39433834Meta-AnalysisFull text (PMC)
Defibrillation strategies for refractory ventricular fibrillation out-of-hospital cardiac arrest: A systematic review and network meta-analysis.
Abuelazm Mohamed T, Ghanem Ahmed, Katamesh Basant E et al. · Ann Noninvasive Electrocardiol · 2023
PMID: 37482919Meta-AnalysisFull text (PMC)
Novel Topical Esmolol Hydrochloride (Galnobax) for Diabetic Foot Wound: Phase 1/2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Parallel-Group Study.
Rastogi Ashu, Kulkarni Sudhir A, Deshpande Supreet K et al. · Adv Wound Care (New Rochelle) · 2023
PMID: 36245145RCT
Topical Esmolol Hydrochloride as a Novel Treatment Modality for Diabetic Foot Ulcers: A Phase 3 Randomized Clinical Trial.
Rastogi Ashu, Kulkarni Sudhir A, Agarwal Sanjay et al. · JAMA Netw Open · 2023
PMID: 37184839RCTFull text (PMC)
Incompatibility of esmolol hydrochloride and furosemide in a central venous access port.
Zhao Bin, Sun Wenyan · Am J Health Syst Pharm · 2014
PMID: 24830993Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Esmolol hydrochloride (substance)
SNOMED CT
35318005
UMLS CUI
C0700606

Clinical Data

This intervention maps to 18 entities in the Healos knowledge graph.

7
Conditions
7
Biomarkers
3
Specialists
0
Symptoms
12
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.